Antipsychotic use and mortality risk in community-dwelling Alzheimer's disease patients: Evidence for a role of dementia severity

Current Alzheimer Research

Volumn 9, Issue 9, 2012, Pages 1106-1116

  Gardette, Virginie ^a,b,c   Lapeyre Mestre, Maryse ^a,b,c   Coley, Nicola ^a,b,c   Cantet, Christelle ^c   Montastruc, Jean Louis ^a,b,c   Vellas, Bruno ^a,b,c   Andrieu, Sandrine ^a,b,c  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b INSERM   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer disease; Antipsychotic agents; Cohort studies; Dementia; Mortality

Indexed keywords

ARIPIPRAZOLE; CYAMEMAZINE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PIPAMPERONE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TIAPRIDE; ZIPRASIDONE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COMMUNITY LIVING; DEMOGRAPHY; DISEASE SEVERITY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

AGED; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; COHORT STUDIES; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 84870199798     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512803569037     Document Type: Article

References (77)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Michael Arrighi H. Forecasting the global burden of Alzheimer's disease. Alzheimer's & Dementia. The Journal of the Alzheimer's Association 3(3):186-191 (2007).
2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366(9503): 2112-2117 (2005).
3. Ballard C, Day S, Sharp S, Wing G, Sorensen S. Neuropsychiatric symptoms in dementia: importance and treatment considerations. Int Rev Psychiatry 20(4): 396-404 (2008).
4. Howard R, Ballard C, O'Brien J, Burns A. Guidelines for the management of agitation in dementia. Int J Geriatr Psychiatry 16(7): 714-717 (2001).
5. Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 23(2):170-177 (2008).
6. Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Gauthier S, et al. Long-term progression of Alzheimer's disease in patients under antidementia drugs. Alzheimers Dement 7(6): 579-592 (2011).
7. Ballard C, Corbett A. Management of neuropsychiatric symptoms in people with dementia. CNS Drugs 24(9): 729-739 (2010).
8. Kamble P, Chen H, Sherer JT, Aparasu RR. Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data. Drugs Aging 26(6): 483-492 (2009).
9. Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based timeseries analysis. CMAJ 179(5): 438-446 (2008).
10. Kamble P, Sherer J, Chen H, Aparasu R. Off-label use of secondgeneration antipsychotic agents among elderly nursing home residents. Psychiatr Serv 61(2):130-136 (2010).
11. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 165(7):844-854 (2008).
12. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev (1): CD003476 (2006).
13. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306(12): 1359-1369 (2011).
14. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355(15):1525-1538 (2006).
15. Ballard CG, Thomas A, Fossey J, Lee L, Jacoby R, Lana MM, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry 65(1):114-119 (2004).
16. Bridges-Parlet S, Knopman D, Steffes S. Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment-controlled pilot study. J Geriatr Psychiatry Neurol 10(3):119-126 (1997).
17. Cohen-Mansfield J, Lipson S, Werner P, Billig N, Taylor L, Woosley R. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med 159(15): 1733-1740 (1999).
18. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657): 31-41 (2009).
19. Trifiro G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res 59(1):1-12 (2009).
20. McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 1314(7076): 266-270 (1997).
21. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 330(7496): 874 (2005).
22. CSM. Atypical antipsychotic drugs and stroke. Committee on Safety of Medicines Journal [serial on the Internet]. 2004 Date 9-3-2004].
23. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebocontrolled trial. Lancet Neurol (2009).
24. FDA. Public Health Advisory: Deaths with anti psychotics in elderly patients with behavioral disturbances. 2005 [updated 2005; cited]; Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/Drug-SafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm
25. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 176(5): 627-632 (2007).
26. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294(15): 1934-1943 (2005).
27. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 146(11): 775-86 (2007).
28. Liperoti R, Onder G, Landi F, Lapane KL, Mor V, Bernabei R, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry 70(10):1340-1307 (2009).
29. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353(22): 2335-23341 (2005).
30. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry14(3): 191-210 (2006).
31. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 169(1): 71-79 (2012).
32. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360(3): 225-235 (2009).
33. FDA. Alert 6/16/2008. 2008 [updated 2008; cited 3 24 2011]; Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116912.htm.
34. Gillette-Guyonnet S, Nourhashemi F, Andrieu S, Cantet C, Micas M, Ousset PJ, et al. The REAL.FR research program on Alzheimer's disease and its management: methods and preliminary results. J Nutr Health Aging 7(2):91-96 (2003).
35. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7): 939-944 (1984).
36. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition. Washington DC; 1994.
37. Folstein MF, Folstein SE, McHugh PR. Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189-198 (1975).
38. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 141(11): 1356-1364 (1984).
39. Beach TG, Honer WG, Hughes LH. Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer's disease? Acta Neuropathol 93(2):146-153 (1997).
40. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of Illness in the Aged. The Index of Adl: A Standardized Measure of Biological and Psychosocial Function. JAMA 185: 914-919 (1963).
41. Guigoz Y, Vellas B, Gary PJ. The Mini Nutritionnal Assessment: a practical assessment tool for grading the nutritional state of elderlypatients. Facts Res Gerontol (suppl 2): 113-143 (1994).
42. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12): 308-314 (1994).
43. Aalten P, Verhey FR, Boziki M, Bullock R, Byrne EJ, Camus V, et al. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord 24(6): 457-463 (2007).
44. Desquilbet L, Meyer L. [Time-dependent covariates in the Cox proportional hazards model. Theory and practice]. Rev Epidemiol Sante Publique 53(1): 51-68 (2005).
45. Levy AR, Tamblyn RM, Abrahamowicz M, McLeod PJ, Fitchett D. Use of time-dependent measures to estimate benefits of betablockers after myocardial infarction. Pharmacoepidemiol Drug Saf 13(9): 623-631 (2004).
46. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158(9): 915-920 (2003).
47. Allison PD. Survival analysis using the SAS system: a practical guideline, p 158-161. publishing S, editor.; 1995.
48. Rossom RC, Rector TS, Lederle FA, Dysken MW. Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc (6):1027-1034 (2012).
49. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat 10(4):577-81 (1991).
50. Pratt N, Roughead E, Salter A, Ryan P. Factors associated with choice of antipsychotic treatment in elderly veterans: potential confounders for observational studies. Aust N Z J Public Health 34(6): 589-593 (2011).
51. Schneeweiss S, Setoguchi S, Brookhart MA, Kaci L, Wang PS. Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data. CNS Drugs 23(2):171-180 (2009).
52. Rhee Y, Csernansky JG, Emanuel LL, Chang CG, Shega JW. Psychotropic medication burden and factors associated with antipsychotic use: an analysis of a population-based sample of community-dwelling older persons with dementia. J Am Geriatr Soc 59(11): 2100-7 (2011).
53. Nonino F, De Girolamo G, Gamberini L, Goldoni CA. Survival among elderly Italian patients with dementia treated with atypical antipsychotics: observational study. Neurol Sci 27(6): 375-380 (2006).
54. Suh GH, Shah A. Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. Int Psychogeriatr 17(3): 429-441 (2005).
55. Haupt M, Cruz-Jentoft A, Jeste D. Mortality in elderly dementia patients treated with risperidone. J Clin Psychopharmacol 26(6): 566-570 (2006).
56. Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry 22(5): 475-484 (2008).
57. Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, Jacoby R, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DARTAD trial). PLoS Med 5(4): e76 (2008).
58. Hollis J, Grayson D, Forrester L, Brodaty H, Touyz S, Cumming R. Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. Am J Geriatr Psychiatry 15(11): 932-941 (2007).
59. Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 164(10): 1568-1576; quiz 623 (2007).
60. Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkala KH. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry 15(5): 416-424 (2007).
61. Trifiro G, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MC. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiol Drug Saf 16(5): 538-544 (2007).
62. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 344: e977 (2012).
63. Musicco M, Palmer K, Russo A, Caltagirone C, Adorni F, Pettenati C, et al. Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease. Dement Geriatr Cogn Disord 31(3): 218-24 (2011).
64. Ames D. Antipsychotics, cognitive decline and death in Alzheimer's disease: the London and South-East Region Alzheimer's Disease longitudinal study. J Neurol Neurosurg Psychiatry 78(1): 2 (2007).
65. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4): 323-337 (2005).
66. Severe ventricular arrhythmia and sudden death on neuroleptics. Prescrire Int 11(61):146-150 (2002).
67. Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, Mor V, et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med 165(6): 696-701 (2005).
68. Straus SM, Sturkenboom MC, Bleumink GS, Dieleman JP, van der Lei J, de Graeff PA, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart 26(19): 2007-2012 (2005).
69. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62(11):1649-7161 (2002).
70. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 24(1):62-69 (2004).
71. Wada H, Nakajoh K, Satoh-Nakagawa T, Suzuki T, Ohrui T, Arai H, et al. Risk factors of aspiration pneumonia in Alzheimer's disease patients. Gerontology (5): 271-276 (2001).
72. Pratt N, Roughead EE, Ramsay E, Salter A, Ryan P. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database. Drug Saf 34(7): 567-575 (2011).
73. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 356(9237): 1219-1223 (2000).
74. Normand SL, Sykora K, Li P, Mamdani M, Rochon PA, Anderson GM. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ 330(7498):1021-1023 (2005).
75. Gardette V, Coley N, Toulza O, Andrieu S. Attrition in geriatric esearch: how important is it and how should it be dealt with? J Nutr Health Aging 11(3): 265-271 (2007).
76. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 170(1): 96-103 (2010).
77. Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio R, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry 68(2):190-197 (2011).